Nkarta, Inc. (NasdaqGS: NKTX)
Health Care · Biotechnology · US
$2.17
-3.56% today · -0.4% 1Y
Nkarta, Inc. (NasdaqGS: NKTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $161.16M and employs 106 people.
Over the last twelve months the share price has lost 0.4%, trading between 1.70 and 3.72.
Tweenvest scores Nkarta, Inc. across four factors: quality 50/100, value 61/100. Its strongest factor is value.
NKTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $161.16M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.58
- Dividend yield
- —
- Beta (5Y)
- 0.94
- 52-week high
- $3.72
- 52-week low
- $1.70
- Avg volume (3M)
- —
- Shares outstanding
- 71.62M
- Employees
- 106
- Next earnings
- —
About Nkarta, Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
- ISIN
- US65487U1088
- Founded
- 2015
- Listed since
- Jul 10, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Burning Rock Biotech LimitedNasdaqGM: BNR | $163.36M | $15.00 | -3.16% |
| GC Cell CorporationKOSDAQ: A144510 | $163.20M | ₩14,600.00 | +0.14% |
| Protara Therapeutics, Inc.NasdaqGM: TARA | $162.81M | $2.77 | +0.54% |
| Bioneer CorporationKOSDAQ: A064550 | $162.42M | ₩8,460.00 | -1.28% |
| curacle co.,ltd.KOSDAQ: A365270 | $161.02M | ₩9,770.00 | -4.22% |
| Pacific Edge LimitedNZSE: PEB | $160.23M | NZ$0.23 | -8.00% |
| Satellos Bioscience Inc.TSX: MSCL | $159.25M | CA$10.71 | -10.82% |
| Coherus Oncology, Inc.NasdaqGM: CHRS | $159.14M | $1.03 | -3.74% |
Figures last refreshed Oct 11, 2026.